Form 8-K · Current report
Humana 8-K, filed Sep 1, 2026
- Filed
- CIK
- 0000049071
- Accession no.
- 0000049071-26-000052
Summary
Humana senior management plans to meet with investors and analysts between September 1 and September 30, 2026, and intends to reaffirm its FY 2026 guidance of at least $6.52 in GAAP diluted EPS or at least $9.00 in adjusted EPS, consistent with guidance issued on July 29, 2026. Humana said it will not comment on 2027 Medicare Advantage Star Ratings (Bonus Year 2028) until CMS releases final data in October.
Key points
- Humana reaffirmed FY 2026 guidance of at least $6.52 GAAP diluted EPS and at least $9.00 adjusted EPS.
- The guidance is unchanged from Humana's July 29, 2026 press release.
- Humana said it does not expect changes to its FY 2026 adjusted EPS guidance but does expect potential changes to GAAP EPS guidance due to value creation and other strategic initiatives.
- Humana will not comment on 2027 Medicare Advantage Star Ratings until CMS releases final data in October.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
From the filing
Item 7.01. Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between September 1, 2026 and September 30, 2026. During these meetings, the Company intends to reaffirm its guidance of at least $6.52 in diluted earnings per common share (“EPS”) or at least $9.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2026 (“FY 2026”). This guidance is consistent with the guidance issued in Humana’s press release dated July 29, 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.